Pharma draws battle lines in NICE £20 million limit row
When plans were announced for a cap on the cost of new drugs in England made available on the National Health Service (NHS) in March, pharma companies were roundly critical of the proposals.
The plan would see drugs which are recommended for NHS funding by the National Institute for Health and Care Excellence (NICE) face an additional negotiation process for medicines if they are likely to cost the NHS more than £20 million ($25.8 million) in any of the first three years of use.
In response to recent reports in the UK media that a legal challenge was being prepared by drugmakers to fight the introduction of this extra negotiating hurdle, the Association of the British Pharmaceutical Industry (ABPI), which represents research-based pharma in the UK, confirmed that it has applied for a judicial review.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze